WaveMan
WaveMan · Company
APYX · Apyx Medical Corp
> Search tickers & screens ⌘K
LIVE
← All companies

APYX Apyx Medical (APYX) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0000719135
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
34
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $71.0K priced

Apyx Medical insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Apyx Medical Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
HILL MATTHEW C
Chief Financial Officer
BUY
2024-08-13 SEC
5,336
$6.0K
+111.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 12, 2023.
  • The trade is 68.1% of the 7,836 shares held after it.
  • No other insider bought within 30 days.
  • 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer HILL MATTHEW C bought about $6.0K of APYX on Aug 13, 2024; 34 funds added in the latest 13F quarter.
HILL MATTHEW C
Chief Financial Officer
BUY
2025-03-03 SECtraded 2024-08-13
6,000
$6.8K
+110.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 12, 2023.
  • The trade is 70.6% of the 8,500 shares held after it.
  • No other insider bought within 30 days.
  • 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer HILL MATTHEW C bought about $6.8K of APYX on Aug 13, 2024; 34 funds added in the latest 13F quarter.
HILL MATTHEW C
Chief Financial Officer
BUY
2023-12-14 SECtraded 2023-12-12
2,500
$5.5K
+6.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 2,500 shares held after it.
  • 1 other insider bought within 30 days.
  • 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer HILL MATTHEW C bought about $5.5K of APYX on Dec 12, 2023; 1 other insider bought within 30 days and 34 funds added in the latest 13F quarter.
Goodwin Charles D. II
Chief Executive Officer
BUY
2023-11-15 SECtraded 2023-11-14
50,000
$78.5K
+19.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 29, 2022.
  • The trade is 55.6% of the 90,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Goodwin Charles D. II bought about $78.5K of APYX on Nov 14, 2023, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 34 funds added in the latest 13F quarter.
Hornsby Todd
Executive Vice President
SELL
2023-06-29 SECtraded 2023-06-26
15,000
$113.4K
-50.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • No other insider sold within 30 days.
  • 34 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Vice President Hornsby Todd sold about $113.4K of APYX on Jun 26, 2023, the largest insider sale at the company on our record; 34 funds added in the latest 13F quarter.
7 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 2 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
34 funds bought in last quarter
below 66% of Medical Devices
Revenue
+9.9% year over year
more than 50% of Medical Devices
Margin
-21.2% net margin
below 54% of Medical Devices
Buybacks
no share repurchases reported
Short interest
0.7% of the float short (float per yahoo 2026-10-26) · 1.2 days to cover · settled 2026-09-30
below 79% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch APYX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-13.8%12M
-19%+10%+39%+68%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns APYX: institutional holders (13F)

13F holdings, latest reported quarter
Nantahala Capital Management, LLC
6,540,496 sh
$29.4M
ROYCE & ASSOCIATES LP
3,274,064 sh
$14.7M
Archon Capital Management LLC
2,644,717 sh
$11.9M
VANGUARD CAPITAL MANAGEMENT LLC
1,534,847 sh
$6.9M
ESSEX INVESTMENT MANAGEMENT CO LLC
1,136,630 sh
$5.1M

Congress trades in APYX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

APYX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

APYX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Taylor Frigon Core Growth Fund
$513.1K position · as of 2026-05-31
1.4%
1290 Essex Small Cap Growth Fund
$1.1M position · as of 2026-07-31
1.0%
Royce Capital Fund - Micro-Cap Portfolio
$965.9K position · as of 2026-06-30
0.7%
Royce Micro-Cap Fund
$2.6M position · as of 2026-06-30
0.6%
Royce Small-Cap Opportunity Fund
$3.1M position · as of 2026-06-30
0.2%
Ultra-Small Company Market Fund
$248.3K position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Charles D. Goodwin
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.2M
$2.1M
$641.5K
+50%
n/a
2024
$976.0K
$509.2K
$675.4K
-32%
n/a
2023
$1.3M
$1.4M
$769.7K
+12%
n/a
2022
$2.2M
-$653.6K
$974.6K
-82%
n/a
2021
$1.6M
$3.2M
$776.1K
+78%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 34 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

APYX financials

Revenue growth
+9.9%
XBRL, annual
Net margin
-21.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$58.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-14.8%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$11.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
4.15x
long-term 2026-06-30 plus current 2023-06-30 (36 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.23x
TTM operating cash flow over long-term 2026-06-30 plus current 2023-06-30 (36 months older than the period end)
Return on equity
-96.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-14.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-7.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$121.9M
market value at close 2026-10-27 on 2026-08-05 shares, plus long-term 2026-06-30 plus current 2023-06-30 (36 months older than the period end), minus cash 2026-06-30
FCF yield
-10.5%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$52.8M$48.1M$52.3M$44.5M
Gross profit$33.0M$29.4M$33.8M$29.1M
Operating income-$6.4M-$18.8M-$17.3M-$23.6M
Net income-$11.2M-$23.5M-$18.7M-$23.2M
EPS (diluted)n/an/a-0.54-0.67
Operating cash flow-$8.0M-$18.0M-$5.2M-$20.3M
Cash$31.7M$31.7M$43.7M$10.2M
Long-term debt$34.8M$33.9M$33.2M$0
SEC XBRL, fiscal years, as known on 2026-10-28

APYX Stock Sonar score 5/7 axes

Find similar shapesCompare

APYX ranks highest on risk and compliance (91st percentile) and growth (50th), and lowest on financial health (27th), among Medical Devices peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
45
Inputs
  • Return on equity-96.4% · 27 pct, sector of 183
  • Return on assets-14.5% · 50 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-7.1% · 58 pct, sector of 188
Financial health
27
Inputs
  • Debt to equity4.15x · 8 pct, sector of 159
  • Cash flow to debt-0.23x · 47 pct, sector of 150
Growth
50
Inputs
  • Revenue growth, YoY+9.9% · 50 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
34
Inputs
  • Funds adding, latest quarter34 · 34 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
91
Inputs
  • Short interest, % of float+0.7% · 81 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+2.9% · 91 pct, sector of 198
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies